Liz Morrell
MA MSc PhD FHEA
Senior Researcher
Liz joined Health Economics Research Centre (HERC) in February 2018, from the Centre for the Advancement of Sustainable Medical Innovation (CASMI) - a policy research group in Oxford’s Radcliffe Department of Medicine. Her work focused on the health economics of cancer drugs, exploring the impact of technology appraisal processes on patient access to drugs, and the value that society places on treating cancer relative to other conditions.
Since joining HERC, Liz has followed two strands of research: economic evaluation of genomic technologies including in low and middle income countries, and using choice experiments to understand patient and clinician behaviour related to antibiotic resistance
Before coming to Oxford, Liz worked as a freelance researcher with clients in pharmaceuticals and education, and as a product development manager in consumer healthcare.
Recent publications
Addition of rituximab to first-line treatment of Burkitt lymphoma in children and young adults in Tanzania: a cost-utility analysis
Journal article
MORRELL L. et al, (2026), Journal of Clinical Oncology Global Oncology
Intention of UK residents to wear facemasks and practise social distancing during the next respiratory virus pandemic
Preprint
Smith DRM. et al, (2026)
Liquid biopsy for the diagnosis of EBV-positive Burkitt's lymphoma in endemic areas.
Journal article
Chamba C. et al, (2026), Nat Med
Is liquid biopsy a cost-effective method to diagnose Burkitt Lymphoma in children and young adults? A health economic evaluation in Tanzania.
Journal article
Jiang J. et al, (2026), BMC Med, 24
Risk stratification in newly-diagnosed myeloma: Is a sequencing panel a cost-effective option for the NHS?
Conference paper
Mcelwee F. et al, (2026), BRITISH JOURNAL OF HAEMATOLOGY, 208, S240 - S241
